ATHA Athira Pharma Inc

USD 3.21 -0.19 -5.588235
Icon

Athira Pharma Inc (ATHA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.21

-0.19 (-5.59)%

USD 0.13B

0.10M

USD 19.00(+491.90%)

USD 3.58 (+11.53%)

Icon

ATHA

Athira Pharma Inc (USD)
COMMON STOCK | NSD
USD 3.21
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.13B

USD 3.58 (+11.53%)

USD 3.21

Athira Pharma Inc (ATHA) Stock Forecast

Show ratings and price targets of :
USD 19.00
(+491.90%)

Based on the Athira Pharma Inc stock forecast from 1 analysts, the average analyst target price for Athira Pharma Inc is USD 19.00 over the next 12 months. Athira Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Athira Pharma Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Athira Pharma Inc’s stock price was USD 3.21. Athira Pharma Inc’s stock price has changed by -2.43% over the past week, +23.46% over the past month and +5.25% over the last year.

No recent analyst target price found for Athira Pharma Inc
No recent average analyst rating found for Athira Pharma Inc

Company Overview Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocy...Read More

https://www.athira.com

18706 North Creek Parkway, Bothell, WA, United States, 98011

65

December

USD

USA

Adjusted Closing Price for Athira Pharma Inc (ATHA)

Loading...

Unadjusted Closing Price for Athira Pharma Inc (ATHA)

Loading...

Share Trading Volume for Athira Pharma Inc Shares

Loading...

Compare Performance of Athira Pharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ATHA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Athira Pharma Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -0.25 (-0.05%) USD127.00B 31.94 20.00

ETFs Containing ATHA

Symbol Name ATHA's Weight Expense Ratio Price(Change) Market Cap
SURI
Simplify Propel Opportuni.. 3.97 % 2.51 % -0.64 (-2.62%) USD0.12B

Frequently Asked Questions About Athira Pharma Inc (ATHA) Stock

Based on ratings from 1 analysts Athira Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on ATHA's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ATHA is USD 19.00 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 19.

Unfortunately we do not have enough data on ATHA's stock to indicate if its overvalued.

The last closing price of ATHA's stock was USD 3.21.

The most recent market capitalization for ATHA is USD 0.13B.

Based on targets from 1 analysts, the average taret price for ATHA is projected at USD 19.00 over the next 12 months. This means that ATHA's stock price may go up by +491.90% over the next 12 months.

Following are ETFs with the highest allocation to Athira Pharma Inc's stock :

SURI

As per our most recent records Athira Pharma Inc has 65 Employees.

Athira Pharma Inc's registered address is 18706 North Creek Parkway, Bothell, WA, United States, 98011. You can get more information about it from Athira Pharma Inc's website at https://www.athira.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...